Company / SG&A Expense
PROKIDNEY CORP. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$56.1M
FY2024
5-year range
$6.0M / $70.9M
FY2020-FY2024
Trend
+25.1%
vs FY2023
Sector context
#151 of 213
Health Care
What the data says
At $56M, PROKIDNEY CORP.'s sg&a expense ranks #63 of 213 in the Health Care sector. Improved from $71M to $56M over the past 2 years.
Based on SEC 10-K filings.
$56M in FY2024 with a 3-year CAGR of +85.0%.
Improved from $71M to $56M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +85.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#63 of 213 in Health CareTop 29% of 213This company $56.1M Sector average $722.3M
▼
-92.2% below sector average
Key checks
Key Insights
- 3-year CAGR of +85.0%, indicating consistent growth.
- In FY2024, sg&a expense increased 25.1% year-over-year.
- Ranks #151 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.00 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $56.1M | +25.1% |
| FY2023 | $44.8M | -36.8% |
| FY2022 | $70.9M | +701.1% |
| FY2021 | $8.9M | +48.0% |
| FY2020 | $6.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026